Salarius Pharmaceuticals Inc. has been granted an extension by the Nasdaq Hearings Panel to regain compliance with exchange listing requirements, specifically regarding their equity standards and minimum bid price. The extension is contingent upon Salarius meeting scheduled milestones, including regaining compliance with the equity standard by early July 2025 and the minimum bid price requirement by early August 2025. Previously, Salarius had received a notice about non-compliance due to their stock's closing bid price being below $1.00 per share for 30 consecutive business days. Following a hearing on June 3, 2025, Salarius is working towards achieving these milestones to maintain their listing on the Nasdaq Capital Market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.